Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2023 - 2025)

Neuphoria Therapeutics (NEUP) has reported Cash from Financing Activities for 3 consecutive years, with $14.7 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash from Financing Activities rose 13242.71% year-over-year to $14.7 million in Q4 2025; TTM through Mar 2026 was $18.6 million, a 134.36% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, down 89.88% from the prior year.
• Cash from Financing Activities was $14.7 million for Q4 2025 at Neuphoria Therapeutics, up from $3.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $14.7 million in Q4 2025 and troughed at -$227338.0 in Q3 2024.
• A 3-year average of $3.5 million and a median of $1.5 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 137.11% in 2024 and jumped 13242.71% in 2025, its largest moves.
• Over 3 years, Cash from Financing Activities stood at $5.6 million in 2023, then plunged by 101.98% to -$111562.0 in 2024, then jumped by 13242.71% to $14.7 million in 2025.
• The last three Cash from Financing Activities figures came in at $14.7 million (Q4 2025), $3.3 million (Q3 2025), and $704675.0 (Q2 2025), per Business Quant data.